8 Things to Know About Johnson & Johnson's Q4 and FY 2018 Financials

@neutrogenaUS/ via Facebook.com
@neutrogenaUS/ via Facebook.com

Johnson & Johnson has reported its Q4 and FY 2018 financial results. 


  • Total sales for the fourth quarter of 2018 were reported at $20.4 billion, up 1% over the previous year
  • Domestic sales increased 1.5%; international sales increased 0.4%


Full-year 2018

  • Total worldwide sales for 2018 came in at $81.6 billion, an increase of 6.7%
  • Domestic sales increased 5.1%, while international sales increased 8.5%


Consumer Segment

  • For full year 2018 consumer sales came in at $13.9 billion, up 1.8% over 2017
  • Domestic and international sales increased 3.5% and .7%, respectively
  • Neutrogena and OGX beauty products were cited among the growth drivers


Looking Forward

  • The company announced 2019 full-year guidance for sales of $80.4 billion to $81.2 billion; as Business Insider notes, this guidance is below some estimates and points to slowing in 2019

Johnson & Johnson  delivered another year of strong operational sales growth of 6.3% and achieved our 35th consecutive year of adjusted operational earnings growth at 9.8% in 2018. This can be attributed to accelerated underlying sales performance across each of our businesses, where we also leveraged our scale across the enterprise to improve margins,” said chairman and CEO Alex Gorsky.

He added: “Looking ahead, the strength of our broad-based business and disciplined approach to portfolio management positions us to continue to fuel investments in innovation that enable us to capitalize on strategic opportunities and deliver strong performance over the long-term.”

More in News